Prevduo is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 5 US drug patents filed from 2023 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 25, 2038. Details of Prevduo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11110054 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(12 years from now) | Active |
| US11938217 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(12 years from now) | Active |
| US10456354 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(12 years from now) | Active |
| US12151020 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(12 years from now) | Active |
| US12383491 | NA |
Oct, 2038
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Prevduo's patents.
Latest Legal Activities on Prevduo's Patents
Given below is the list of recent legal activities going on the following patents of Prevduo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 26 Mar, 2024 | US11938217 |
| Email Notification
Critical | 26 Mar, 2024 | US11938217 |
| Recordation of Patent Grant Mailed
Critical | 26 Mar, 2024 | US11938217 |
| Patent Issue Date Used in PTA Calculation
Critical | 26 Mar, 2024 | US11938217 |
| Recordation of Patent eGrant | 26 Mar, 2024 | US11938217 |
| Mail Patent eGrant Notification | 26 Mar, 2024 | US11938217 |
| Email Notification
Critical | 07 Mar, 2024 | US11938217 |
| Issue Notification Mailed
Critical | 06 Mar, 2024 | US11938217 |
| Dispatch to FDC | 26 Feb, 2024 | US11938217 |
| Application Is Considered Ready for Issue
Critical | 26 Feb, 2024 | US11938217 |
US patents provide insights into the exclusivity only within the United States, but
Prevduo is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Prevduo's family patents as well as insights into
ongoing legal events
on those patents.
Prevduo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Prevduo's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 25, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Prevduo Generics:
There are no approved generic versions for Prevduo as of now.
About Prevduo
Prevduo is a drug owned by Azurity Pharmaceuticals Inc. Prevduo uses Glycopyrrolate; Neostigmine Methylsulfate as an active ingredient. Prevduo was launched by Azurity in 2023.
Approval Date:
Prevduo was approved by FDA for market use on 23 February, 2023.
Active Ingredient:
Prevduo uses Glycopyrrolate; Neostigmine Methylsulfate as the active ingredient. Check out other Drugs and Companies using Glycopyrrolate; Neostigmine Methylsulfate ingredient
Dosage:
Prevduo is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML) | SOLUTION | Prescription | INTRAVENOUS |